• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Infectious Diseases, Other  • Corneal Disorders  • Articles for Residents  • Drug Therapy  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

A Prospective Open-Label Study

David Lau, BPharm, MRPharmS; Mervyn Fedinands, MBBS(Hons); Lok Leung, BPharm(Hons); Robert Fullinfaw, BSc, DSc; David Kong, PhD, BPharm, MPharm; Geoff Davies, BPharm; Mark Daniell, MBBS, MS, FRACS, FRANZCO

Arch Ophthalmol. 2008;126(3):343-346.

Objective  To determine the therapeutic efficacy of adjuvant use of voriconazole, 1%, eyedrops in the treatment of refractory fungal keratitis.

Methods  A prospective open-label trial was conducted to determine voriconazole levels obtained in human aqueous humor after administration of a 1% solution, preserved with 0.01% benzalkonium chloride, every 6 hours for 3 days, or hourly for 4 doses. Ten participants were selected among patients scheduled to undergo elective anterior segment surgery, and samples were tested using validated high-performance liquid chromatography.

Results  The mean (SD) voriconazole concentrations after hourly dosing (n = 5) was 1.90 (1.12) µg/mL and after a single dosing every 6 hours (n = 5) was 0.94 (1.21) µg/mL, respectively. The mean (SD) sampling times after the last administration of eyedrops were 1.1 (0.5) hours after hourly dosing and 2.1 (0.6) hours after a single dosing every 6 hours.

Conclusions  Voriconazole, 1%, eyedrops are well tolerated and penetrate into human aqueous humor when administered at hourly or 6-hourly intervals. They are effective in treating Candida and Aspergillus keratitis, are substantially more affordable than oral therapy, and have less potential to cause systemic adverse effects.

Author Affiliations: Department of Pharmacy, Eastern Health (Mr Lau); Departments of Ophthalmology (Messrs Fedinands and Daniell) and Pharmacy (Messrs Leung and Davies), Royal Victorian Eye and Ear Hospital; Department of Specialist Chemistry, Royal Melbourne Hospital (Dr Fullinfaw); and Department of Pharmacy Practice, Monash University (Dr Kong), Melbourne, Australia.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treatment of Alternaria Keratitis with Intrastromal and Topical Caspofungin in Combination with Intrastromal, Topical, and Oral Voriconazole
Neoh et al.
The Annals of Pharmacotherapy 2011;45:e24-e24.
ABSTRACT | FULL TEXT  

Comparison of Natamycin and Voriconazole for the Treatment of Fungal Keratitis
Prajna et al.
Arch Ophthalmol 2010;128:672-678.
ABSTRACT | FULL TEXT  

Successful Use of Topical Voriconazole 1% Alone as First-Line Antifungal Therapy Against Candida albicans Keratitis
Al-Badriyeh et al.
The Annals of Pharmacotherapy 2009;43:2103-2107.
ABSTRACT | FULL TEXT  

Stability of extemporaneously prepared voriconazole ophthalmic solution
Al-Badriyeh et al.
Am J Health Syst Pharm 2009;66:1478-1483.
ABSTRACT | FULL TEXT  

Prospective Open-Label Study of the Administration of Two-Percent Voriconazole Eye Drops
Al-Badriyeh et al.
Antimicrob. Agents Chemother. 2009;53:3153-3155.
ABSTRACT | FULL TEXT  

Successful Salvage Treatment of Scedosporium apiospermum Keratitis with Topical Voriconazole After Failure of Natamycin
Al-Badriyeh et al.
The Annals of Pharmacotherapy 2009;43:1139-1142.
ABSTRACT | FULL TEXT  

Preparation and Stability of Voriconazole Eye Drop Solution
Dupuis et al.
Antimicrob. Agents Chemother. 2009;53:798-799.
ABSTRACT | FULL TEXT